Irbesartan
- Generic Name
- Irbesartan
- Brand Names
- Avalide, Avapro, Ifirmacombi, Karvea, Karvezide, Irbesartan Teva, Ifirmasta (previously Irbesartan Krka), Irbesartan Zentiva (previously Irbesartan Winthrop), Aprovel
- Drug Type
- Small Molecule
- Chemical Formula
- C25H28N6O
- CAS Number
- 138402-11-6
- Unique Ingredient Identifier
- J0E2756Z7N
- Background
Irbesartan is an angiotensin receptor blocker (ARB) indicated to treat hypertension or diabetic nephropathy. It can also be used as part of a combination product with hydrochlorothiazide for patients not well controlled or not expected to be well controlled on monotherapy. Unlike angiotensin converting enzyme inhibitors, ARBs are not associated with a dry cough.
Irbesartan was granted FDA approval on 30 September 1997.
- Indication
Irbesartan is indicated to treat hypertension and diabetic nephropathy in hypertensive patients with type 2 diabetes, elevated serum creatinine, and proteinuria. A combination product with hydrochlorothiazide is indicated for hypertension in patients with uncontrolled hypertension with monotherapy or first line in patients not expected to be well controlled with monotherapy.
- Associated Conditions
- Diabetic Nephropathy, Hypertension
Remission Clinic in Proteinuric Chronic Nephropathies
- Conditions
- Chronic Kidney Disease
- Interventions
- First Posted Date
- 2016-03-29
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Mario Negri Institute for Pharmacological Research
- Target Recruit Count
- 1500
- Registration Number
- NCT02721342
- Locations
- 🇮🇹
Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò, Ranica, Bergamo, Italy
🇮🇹Ospedale Campo di Marte - USL 2 - U.O. Nefrologia, Lucca, Italy
🇮🇹Ospedale di Circolo Fondazione Macchi - U.O. Nefrologia e Dialisi, Varese, Italy
A Prospective, Single-center, Randomized, Controlled Study of Sevelamer Carbonate in the Lipid Metabolism and Uric Acid Treatment of Obesity-Related Glomerulopathy
- Conditions
- Obesity and Glomerulopathy
- Interventions
- Drug: Low dosage Sevelamer Carbonate + IrbesartanDrug: High dosage Sevelamer Carbonate + Irbesartan
- First Posted Date
- 2015-12-31
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- Zhi-Hong Liu, M.D.
- Target Recruit Count
- 4
- Registration Number
- NCT02644486
- Locations
- 🇨🇳
Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu, China
Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE)
- Conditions
- Ehlers-Danlos Syndrome, Vascular Type
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 61
- Registration Number
- NCT02597361
- Locations
- 🇫🇷
CHU DE BORDEAUX - Hopital Saint Andre, Bordeaux, France
🇫🇷CHU DE LYON - Hopital Femme Mere Enfant, Bron, France
🇫🇷CHU DE TOURS - Hopital Trousseau, Chambray-les-Tours, France
Effectiveness of Avapro in Obese Normotensive/Hypertensive African Americans
- Conditions
- Blood PressureHypertensionObesityStress, Psychological
- Interventions
- Other: Placebo
- First Posted Date
- 2015-03-11
- Last Posted Date
- 2019-06-21
- Lead Sponsor
- Augusta University
- Target Recruit Count
- 30
- Registration Number
- NCT02386293
- Locations
- 🇺🇸
Augusta University, Augusta, Georgia, United States
Angiotensin II Antagonist in Severe Sepsis
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2013-11-25
- Lead Sponsor
- University of Salerno
- Target Recruit Count
- 300
- Registration Number
- NCT01992796
- Locations
- 🇮🇹
Università di Salerno, Salerno, Italy
The Oxford Marfan Trial
- First Posted Date
- 2013-09-24
- Last Posted Date
- 2015-06-09
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 56
- Registration Number
- NCT01949233
- Locations
- 🇬🇧
University of Oxford, Oxford, Oxfordshire, United Kingdom
🇬🇧John Radcliffe Hospital, Oxford, Oxfordshire, United Kingdom
Drug Interaction Between Irbesartan and Hydrochlorothiazide
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2013-05-21
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Damanhour University
- Target Recruit Count
- 18
- Registration Number
- NCT01858610
- Locations
- 🇪🇬
Pharmaceutics Department, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt
Pharmacokinetic Drug Interaction Study Between Gemigliptin and Irbesartan After Oral Administration in Healthy Male Subjects
- First Posted Date
- 2013-04-08
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- LG Life Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT01825850
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fed Conditions
- First Posted Date
- 2012-10-23
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 34
- Registration Number
- NCT01712100
- Locations
- 🇺🇸
Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research), San Antonio, Texas, United States
Crossover Bioequivalence Study of Irbesartan HCTZ 300/25 mg Tablets Under Fasted Conditions
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2012-10-23
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 37
- Registration Number
- NCT01712139
- Locations
- 🇺🇸
Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research), San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.